INTRODUCTION
============

Drug-resistant tuberculosis (MDR-TB) has emerged as an important global health concern and is on the rise throughout the world \[[@R1]\]. According to the 2012 World Health Organization (WHO) report, 3.7% of new TB cases (patients who have never had treatment for TB, or had been on anti-TB treatment for less than four weeks) \[[@R2]\] and about 20% of retreatment patients (TB patients who had been cured for one month or more) \[[@R2]\] had MDR-TB in 2012. Nine percent of these patients in 2012 had extensive drug-resistant tuberculosis (XDR-TB) \[[@R3]\].

To be defined as MDR-TB, the patient shows resistance to at least isoniazid (INH) and rifampin (RMP) \[[@R3]\]. Furthermore, XDR-TB is defined as resistant to INH, RMP, any fluoroquinolone and any second-line injectable medications (*i.e.* amikacin, capreomycin and kanamycin) \[[@R4]\]. Treatment of MDR-TB is a costly and time-consuming (18 months) process which can be associated with numerous complications. The overall economic burden of an MDR-TB patient is high and if left untreated, MDR-TB has an estimated 80% fatality rate \[[@R5]\].

It is notable that the highest rates of resistance in 2008 have been reported in Eastern Europe and East Mediterranean regions \[[@R6]\]. In Iran (2011), the proportion of MDR-TB cases of new and retreated TB cases were reported to be 5% and 38.3%, respectively \[[@R5]\]. Due to the proximity to countries such as Azerbaijan, Armenia and Pakistan, which are among the 27 countries with the highest MDR-TB burden in world, the control of drug resistance is very pivotal in Iran \[[@R7]\].

The main strategy to control MDR-TB is the detection of drug resistance and to prescribe an effective drug course for patients \[[@R8]\]. Previous and inadequate treatment is of the main factors contributing to MDR-TB development \[[@R9]\].

The gold standard in MDR-TB determines is 1% proportion of Löwenstein-Jensen medium. Developed in the 1960s, the Löwenstein-Jensen medium is inexpensive and easy to perform \[[@R10]\]. In the present study, we evaluated the patterns of resistance to TB drugs based on the 1% proportion method among pulmonary TB patients from five provinces of patients in near the Iranian border; in addition, we analyzed the impact of geographic and demographic factors on TB drug resistance.

METHODS
=======

Sampling Method
---------------

A cross-sectional survey was conducted on pulmonary TB patients in five Iranian west and northwestern provinces (East Azerbaijan, West Azerbaijan, Ardabil, Kurdistan and Kermanshah) that had been referred of rural and urban health centers to TB lab centers of province from April 2011 to March 2013. Proximity to the neighboring country of Azerbaijan and Iraq with high prevalence of TB and TB- drug resistance renders the need of study in this region. The University Ethics Committee code of study was 1391/6/18/5/4/5375.

Assuming a significance level p=0.05, prevalence of MDR-TB p=0.05 \[[@R4]\], margin of error d=0.018, and considering the likelihood of missing cases, 300 positive smear tuberculosis patients with HIV negative test (ELISA test) were estimated based on proportional simple random sampling. The required sample size for each province was determined based on TB prevalence in the provinces in 2010; the sampling method in provinces was systematic on the basis of alphabetical order of patients' name.

Laboratory Analysis
-------------------

Sputum- positive pulmonary TB was defined as TB in patients with at least two initial sputum smear examinations positive for acid-fast bacilli (AFB), one sputum smear test positive for AFB and radiographic abnormalities consistent with active pulmonary TB, or one sputum smear specimen positive for AFB and culture positive for *Mycobacterium tuberculosis* \[[@R9]\]. Two smears with the highest bacterial count were cultured on Lowenstein Jensen (LJ) culturing medium and one culture was selected for drug susceptibility test. The MTB complex strains were identified by culturing on LJ medium containing P-Nitro Benzoic acid (PNB). But differentiation of MTB from other members of the MTB complex was identified based on niacin test and Nitratase test. The samples containing non-tuberculosis mycobacterium were excluded from this study. Drug susceptibility was tested on LJ medium containing Isoniazid (INH); 0.2mg/l, Rifampicine (RMP);40mg/l, Ethambutol (EMB);2mg/l, Streptomycin (SM);4mg/l and second line drugs including Kanamycin; 30 mg/l, Capreomycin;40 mg/l, Ofloxacin;20 mg/l and Ciprofloxacin; 2 mg/l according to the proportion method based on WHO/IUTLD guideline \[[@R11], [@R12]\].

Demographic Variable
--------------------

The data related to clinical, demographic and environmental characteristics were provided using the information mentioned in the patient's records as well as personal or telephone interviews. It should be said that the data of the patients under 15 years was completed by the help of the patient's parents and the information of the deceased patients was filled in by the closest person to the patient. In a pilot study, the validity of the questionnaire was evaluated as confirmed by expert professors and its reliability was assessed using statistical reliability test (Cronbach's alphas=0.92.

Statistical Analysis
--------------------

Univariate and multiple logistic regressions were used to compare the effect of demographic and geographical factors on drug resistance considering significance level of 0.05 using SPSS-18 software (IBM, Armonk, New York, USA).

RESULTS
=======

Out of 300 patients with MTB, 286 had a positive culture. In the drug resistance analysis sample, six cultures were contaminated and therefore 280 cases were available for drug resistance analysis.

To populate our study, 96 patients (34.29%) from East Azerbaijan, 53 (18.93%) from Kermanshah, 45 (16.08%) from West Azerbaijan, 56 (20.0%) from Kurdistan and 30 (10.72%) from Ardabil provinces were selected. All of the patients were HIV negative.

The overall frequency of new and retreatment TB groups was 253 (90.36%) and 27 (9.64%) patients, respectively. The mean age of patients available for drug resistance analysis was 52.03 years and 152 patients (54.3%) were male. Resistance to RMP was found in 11.8% of cases (33 patients) and following by Streptomycin (STM) with 10.7% (30 patients) had the highest proportions among anti-tuberculosis drugs while resistance to ethambutol (EMB) in 3.2% (9 patients) showed the least rate of resistance (see Table **[1](#T1){ref-type="table"}**). Eleven percent of new TB cases (28 patients) and 40.7% of retreatment TB cases (11 patients) were resistant to any TB drug.

In the retreatment TB group, resistance to INH was found in 23.1% (6 cases), RMP: 15.4% (4 cases), STM: 15.4% (4 cases) and EMB: 0%. MDR-TB and XDR-TB prevalence was 23.1% (6 cases) and 3.8% (1 case), respectively. In regards to the new TB group, any resistance to INH was 6.7% (17 cases), RMP: 4.33% (11 cases), EMB: 2.77% (7 cases) and STM: 7.9% (20 cases). MDR-TB and XDR-TB prevalence was 2.38% (6 cases) and 0%, and total poly-resistance other than MDR was 1.17% (3 cases).

The prevalence of drug resistance by various provinces is shown in Table **[1](#T1){ref-type="table"}**. Resistance to INH was found to be the most prevalent in the province of Ardebil (13.33%), RMP (14%) and EMB (5.3%) in Kurdistan, and STM (13.2%) in Kermanshah. Also MDR-TB prevalence was the most common in Ardebil (6.67%). There wasn't any relationship between different provinces and any TB drug resistance (p\>.05)

We analyzed the effect of demographic and geographical factors on resistance to TB drugs by univariate and multiple logistic regression tests (See Table [2](#T2){ref-type="table"}). In the multiple models, variables with a p-value of ≤0.1 were included and reanalyzed. The odds of resistance to one or more TB drugs was significantly high in retreatment cases compared to newly diagnosed cases in univariate (CI 95% 2.42 to 13.67) and multiple regression analyses (CI 95%:1.43 to 25.0). Migration history from village to city and smoking increased odds of drug resistance as well (CI 95% OR: 1.05 to 4.2) and (CI 95% OR: 1.36 to 5.5) in univariate regression analysis (See Table [**2**](#T2){ref-type="table"}).

DISCUSSION
==========

The emergence of TB drug resistance is a great catastrophe because it requires the use of second-line drugs which are less efficient, have longer treatment periods, higher expenses and patients run the risk of developing hepatotoxicity \[[@R13], [@R14]\].On the other hand, MDR-TB has increased throughout the world over the past few decades \[[@R4]\]. According to the global project on anti-TB drug resistance surveillance in 2009, the median prevalence of resistance to any drug was 11.1% and 25.1% in new and previously treated cases, respectively \[[@R15]\].

However, it seems that Iran has a moderate drug resistance rate in new cases compared to global estimates, but proximity to the Azerbaijan Republic (with a prevalence of 56.3% and 84.4% drug resistance in new and retreated cases, respectively) \[[@R15]\] necessitates the task of controlling drug resistance

Also MDR-TB in new and previously treated cases (2.38% and 23.1% for new and previously treated cases, respectively in our study) was reported as lower than the rates reported for the WHO Eastern Mediterranean region \[[@R16]\].

The average of MDR-TB prevalence in Iran (studies of 1997 to 2010) was 18.3% \[[@R13], [@R14], [@R17]-[@R21]\]. The discrepancy of drug resistance with other Iranian studies can be explained by the diversities in the source population. In the available studies from Iran, the studies consisted of Iranian and Afghan patients \[[@R13], [@R20], [@R21]\]. As reported by the WHO global project over 1999-2002, Afghan patients comprised a high percentage of MDR-TB cases in Iran \[[@R22]\]. In our study, however, we solely screened and sampled Iranians.

We found that a case of XDR among MDR-TB patients that should be a warning sign. XDR-TB is documented in 2006 by Masjedi, *et al*. in Iran (10.9% of MTB strains) \[[@R21]\]. Globally, 10% of all MDR-TB cases are XDR, (ranging from 4% in Armenia to 23.7% in Estonia) \[[@R15]\]. In our study, the prevalence of drug resistance was the highest for RMP following by STM. This result is almost consistent with other Iranian studies \[[@R13], [@R14], [@R17]-[@R21]\].

Different studies in the analysis of various factors on TB drug resistance such as immigration, age, sex and smoking on drug resistance have yielded conflicting results \[[@R13], [@R17], [@R20], [@R23]-[@R26]\], but MDR risk factors have not been fully investigated in Iran \[[@R23]\]. In consistency with our study, immigration and smoking have been suggested as a leading factor in increasing prevalence of MDR-TB in some countries \[[@R25]-[@R27]\]. History of TB previous treatment was one of the most important risk factors for development of drug-resistant TB in consistency with some studies \[[@R18], [@R20], [@R24], [@R28], [@R29]\].

CONCLUSION
==========

As a result, in our study, the proportion of TB drug resistance in new cases was similar to global estimates, while drug resistance in retreated cases was about 1.6 times the global rate. In this study, smokers and those who had a history from village to city were high-risk groups in the occurrence of TB drug resistance. Knowledge of drug resistance patterns for new and previously treated cases is critical for the effective control of MDR-TB.
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###### 

Drug resistance pattern among pulmonary MTB patients.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                         Total (280)\   East Azerbaijan (96)\   West Azerbaijan (45)\   Ardebil (30)\   Kermanshah(53)\   Kurdistan (56)\
                                                                         n (%)          n (%)                   n (%)                   n (%)           n (%)             n (%)
  ---------------------------------------------------------------------- -------------- ----------------------- ----------------------- --------------- ----------------- -----------------
  Any resistance to Isoniazid (INH)                                      28(10.0)       8(8.33)                 4(8.9)                  4(13.33)        5(9.43)           7(12.5)

  Any resistance to Rifampicin (RMP)                                     33(11.8)       6(6.25)                 7(17.5)                 4(13.33)        9(16.98)          7(14.0)

  Any resistance to Etambutol (EMB)                                      9(3.2)         2(2.08)                 0(0.0)                  2(6.7)          2(3.77)           3(5.3)

  Any resistance to Streptomycin (STM)                                   30(10.7)       9(9.37)                 5(12.5)                 3(10.0)         7(13.2)           6(10.71)

  Total Multidrug Resistance (MDR)                                       12(4.3)        3(3.12)                 2(4.44)                 2(6.67)         3(5.66)           2(3.57)

  Total poly- resistance other than MDR                                  4(1.43)        1(1.04)                 0(0.0)                  1(3.33)         1(1.9)            1(1.79)

  Any drug resistant to both of FQ\* and any 2-LI\* in MDR-TB patients   1(0.36)        1(1.04)                 0(0.0)                  0(0.0)          0(0.0)            0(0.0)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Fluroquinolones: Ofloxacin, Levofloxacin \* Injectable agent: Streptomycin, Kanamycin, Amikacin, Capreomycin

###### 

Analyzing of demographic and clinical characteristics on TB drugs resistance among pulmonary MTB patient.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                         Any drug resistance (n=38)   Drug susceptible\   Univariate analysis   Multiple analysis                                        
                                                                                (n= 242)                                                                                           
  ------------------------------ ----------------- ---------------------------- ------------------- --------------------- ------------------- ------ -------------- -------------- ------
  Gender                         Male              26(68.4)                     126 (52.0)          1                     \-                  \-     1              \-             \-

  Female                         12(31.6)          116(48.0)                    2.0                 0.96 to 4.13          0.06                0.9    0.06 to 13.1   0.95           

  Age                            Mean (Year)       52.29(22.8)                  49.24(21.2)         .99                   0.97-1.02           0.64   1.02           0.93 to 1.08   0.71

  Provinces                      East Azerbaijan   12(31.58)                    84(68.42)           1                     \-                  \-     \-             \-             \-

  West Azerbaijan                7(18.42)          40(81.58)                    1.2                 0.45 to 3.35          0.69                \-     \-             \-             

  Ardebil                        5(13.16)          25(86.84)                    1.4                 0.45 to 4.35          0.56                \-     \-             \-             

  Kurdistan                      7(18.42)          48(81.58)                    1.02                0.37 to 2.77          2.77                \-     \-             \-             

  Kermanshah                     7(18.42)          49(81.58)                    1                   0.36 to 2.7           1                                                        

  Married status                 Single            6(15. 7)                     51(21.0)            1                     \-                  \-     \-             \-             \-

  Married                        27 (71.1)         148(61.2)                    0.65                0.25 to 1.65          0.36                \-     \-             \-             

  Divorced/Died spouse           5(13.2)           43(17.8)                     1.0                 0.29 to 3.55          0.98                                                     

  Income (on married patients)   Zero              9(25.0)                      65(28.4)            1                     \-                  \-     \-             \-             \-

  \<100\$                        18(50.0)          93(40.6)                     0.72                0.3 to 1.69           0.44                \-     \-             \-             

  ≥100\$                         9(25.0)           71(31.0)                     1.0923              0.41 to 2.9           0.86                \-     \-             \-             

  SES\*                          Mean(SD)          6.9(3.01)                    6.47(3.7)           1.04                  .89 to 1.2          0.67   0.96           0.7 to 1.29    0.78

  History of Migration           No                18(47.4)                     170(70.0)           1                     \-                  \-     \-             \-             \-

  Yes                            20(52.7)          73(30.0)                     2.09                1.05 to 4.2           0.037               0.96   0.28 to 3.3    0.95           

  Smoking                        No                19(0.5)                      177(72.8)           1                                                1              \-             \-

  Yes                            19(0.5)           65(27.2)                     2.7                 1.36to 5.46           0.005               1.16   .08 to 16.68   0.92           

  Vaccination history            No                20(68.9)                     131(71.97)          1                     \-                  \-     1              \-             \-

  Yes                            9(31.1)           51(28.13)                    1.2                 0.49 to 2.7           0.739               2.48   0.85 to 1.23   0.81           

  Treatment group\*              New               27(71.1)                     226(93.4)           1                     \-                  \-     1              \-             \-

  Other                          11(28.9)          16(6.6)                      5.75                2.42 to 13.67         0.0001              5.76   1.43 to 25     0.025          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*SES; Social-Economic status combining of patient Job (Regardless housekeeper job) and education status, spouse Job (Regardless house keeper job) and education status and family income among married patients.(Grading: Job; 1:Unemployment, 2: Unskilled worker,3:Semi and skilled worker,4: Staff education . Education status; 1: Illiterate, 2: Reading, 3: Middle school, 4: Diploma, 5: Upper diploma. Family income; 1: \<117 USD, 2:117-156 USD, 3: 157-313 USD, 4:\> 313 USD.

\*Treatment group; New: never been treated for TB or have taken anti-TB drugs for less than 1 month previously treated (retreatment): have received 1 month or more of anti-TB drugs in the past.
